Renal denervation to treat resistant hypertension: Guarded optimism

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 7, 2012, Pages 501-510

  Thomas, George ^a   Shishehbor, Mehdi H ^a   Bravo, Emmanuel L ^a   Nally, Joseph V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHETER ABLATION; HUMAN; HYPERTENSION; INNERVATION; KIDNEY; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL ARTERY; REVIEW; SYMPATHECTOMY;

CATHETER ABLATION; HUMANS; HYPERTENSION; KIDNEY; RENAL ARTERY; SYMPATHECTOMY;

EID: 84864012584     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.12040     Document Type: Review

References (33)

1. Chobanian AV, Bakris GL, Black HR, et al; National Heart,Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. National Center for Health Statistics. Vital Health Stat 13(169) 2011. http://www.cdc.gov/nchs/data/series/sr_13/sr13_169.pdf. Accessed April 24, 2012.
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
4. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
5. Calhoun DA, Jones D, Textor S, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
6. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152:1501-1504.
7. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54:1195-1201.
8. Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977; 56:691-698.
9. Kon V. Neural control of renal circulation. Miner Electrolyte Metab 1989; 15:33-43.
10. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 2000; 75:S2-S6.
11. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34:724-728.
12. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 2004; 287:H695-H703.
13. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983; 245:F1-F14.
14. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
15. Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
16. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917.
17. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension 2011; 58:e19; author reply e20.
18. Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011; 58:1176-1182.
19. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension (letter). N Engl J Med 2009; 361:932-934.
20. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011; 100:1095-1101.
21. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011; 29:991-996.
22. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123:1940-1946.
23. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59:901-909.
24. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58:559-565.
25. Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-inman experience. Clin Res Cardiol 2012; 101:63-67.
26. Herring D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; May 17. [Epub ahead of print]
27. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011; 100:1049-1057.
28. Chapman N, Dobson J, Wilson S, et al; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
29. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
30. Papademetriou V, Doumas M, Faselis C, et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens 2011; 2011:964394.
31. Ng MM, Sica DA, Frishman WH. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension. Cardiol Rev 2011; 19:52-57.
32. US National Institutes of Health. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3). http://www.clinicaltrials.gov/ct2/show/NCT01418261. Accessed June 7, 2012.
33. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 trial. Clin Cardiol 2012 May 9. [Epub ahead of print]